Trinity’s Evidence and Outcomes solution strategically plans, executes and deploys evidence to scientifically and holistically inform the product’s value strategy in the marketplace. Leveraging best-in-class, publication-quality primary and secondary research methods, we help products realize value across the lifecycle. We help our customers proactively produce evidence to drive product awareness, adoption and utilization, and overcome potential roadblocks and challenges.

Trinity offers a complete solution for Health Economics and Outcomes Research (HEOR) from strategy development to tactics such as field tool development and deployment, calculators and health economics models. We work with our customers across all phases of a product’s lifecycle: from early clinical development all the way to launch and post-launch. Our dedicated HEOR team is globally recognized for its expertise – led by an economist, presents annually at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and has authored numerous white papers and peer reviewed journal articles. For more information, please click here:

HEOR Strategy 

We help customers effectively navigate contemporary challenges around value and access by strategically planning, executing, and deploying HEOR to maximize their product’s value story. 

Developing the product value story begins with a strategic roadmap that lays out each step of gathering strategic evidence. Our roadmap includes conducting value modeling, strategically incorporating Voice of Customer (VOC) research, leveraging real-world data and evidence (RWD/E) and scientifically communicating the product’s value in industry, clinical and payer forums, here in the US and around the globe.   

Trinity integrates a multi-disciplinary suite of capabilities including secondary research (peer-reviewed literature, real-world evidence/claims/Big Data) and primary research with physicians, payers, patients and caregivers, as well as advanced statistics. 

Trinity’s HEOR team features multiple PhD-level experts and has conducted more than 70 HEOR projects in 2018 alone — developing compelling Value Dossiers and Presentations, publishing epidemiology and Cost of Care studies, and developing transparent Budget Impact models. We consistently deliver high-quality insights and products to meet internal and external stakeholder needs.

Evidence Generation Plan

Evidence Generation Plans help customers meet the evidentiary needs of the product, differentiate it from currently available treatments and communicate its value proposition. Trinity is particularly effective at identifying “Must Have” evidence by geography and stakeholder type, and supporting organizational alignment through creative and high-impact workshops, in order to create an actionable and well-resourced plan.

We convene discussions with both external and internal stakeholders to create a detailed evidence generation plan that includes the type of studies (many of which Trinity has the capability to execute internally), their timing, and the internal stage gates. We deliver the plan to customers through a dynamic, cross-functional workshop that aligns organizations around priorities and resources and serves as a compelling “call to action” prior to finalization. 

Burden of Illness

Trinity’s Burden of Illness projects support disease awareness efforts and act as foundational information for both medical and commercial teams. Our methodologies leverage Big Data to generate publication-quality insights on resource utilization, cost, adherence, incidence, etc. Primary market research including patients and caregivers helps paint a full picture of the disease, clinical symptomology and its impact on social, mental/emotional wellness as well as the ability to work and attend school. Serving as strategic foundations to drive downstream product strategy—from a HEOR and Commercial lens—Burden of Illness projects inform the product’s value proposition. 

Additional projects include Systematic and Targeted Literature Reviews, Value Dossier Development, Budget Impact Models, cost-effectiveness (CE) models, Medical Chart Audits, Claims/RWE projects to inform disease epidemiology, cost of care, and comparative effectiveness.